Phase II study of gefitinib combined with cisplatin and pemetrexed in patients with advanced non-squamous, non-small cell lung cancer acquired resistance to first line gefitinib monotherapy.

Trial Profile

Phase II study of gefitinib combined with cisplatin and pemetrexed in patients with advanced non-squamous, non-small cell lung cancer acquired resistance to first line gefitinib monotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 May 2016

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Nov 2011 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 03 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top